ÃâÒßѧÊÔÌâ
P"+K'B7K3 Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£©
O-<nLB!Wf 1. Fas(CD95)/FasL
jsw0"d( 2. common chain of cytokine receptor
{
%af 3 . TCR/CD3 complex
KMV&c 4. negaive selection of thymocytes
p=f8A71 5. artificial active immune
XSo$;q\ 6. anti-idiotypic
3Et t9fBd 7. IgSF
zCpXF<_C 8. Integrin
W}> wRy 9. chemokine
Ap%tm)@1 10. B7/CD28
f`,isy[ ¶þ. ÎÊ´ðÌ⣨ÿÌâ12·Ö£¬¹²60·Ö£©
rp,PhS 1. ±È½ÏMHC¢ñºÍMHC¢òÀ࿹ԲÎÓëµÄ¼Ó¹¤Ìá³Ê¿¹ÔµÄ¹ý³Ì¡£
|(UkI?V 2. ±È½ÏCTLºÍNKɱÉ˰Ðϸ°ûʱʶ±ðºÍɱÉË»úÖÆµÄÌØµã¡£
@:G#[>nKe 3. ±È½ÏÃâÒßѧ¼ì²â·¨ºÍÉúÎïѧ»îÐÔ¼ì²â·¨¼ì²âϸ°ûÒò×ÓµÄÓÅȱµã¡£ 4. ·¢ÏÖÒ»ÖÖеİ×ϸ°û·Ö»¯¿¹Ô»òÖ×ÁöÏà¹Ø¿¹Ô,²¢ÖƱ¸Á˵¥¿Ë¡¿¹Ìå,ÊÔÉè¼ÆÊµÑé·½°¸¿Ë¡´Ë»ùÒò¡£
!"
7ip9a 5. Ñ¡ÔñÏÂÊöÖÐÒ»¸öרÌâ,ÐðÊöÎÒ¹úÔÚÕâÒ»Ñо¿ÁìÓòµÄÏÖ×´¼°ÃæÁÙµÄÌôÕ½
ZklZU,\!|v
;{Su:Ixg 1)Ö×ÁöÃâÒߣ»(2)»ùÒòÖÎÁÆ£»(3)CD¿¹Ô¡£
CXhE+oS5z' µÚËľüÒ½´óѧһ¾Å¾ÅÆßÄ격ʿÑо¿ÉúÈëѧ¿¼ÊÔÃâÒßѧÊÔÌâ
)\Ay4d Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£©
JnZlz?}^ 1. B7/CD28
#~@Cl9[)D 2. Th1 subset
V|zatMHs 3. seven predicated transmembrane domain receptor superfamily£¨STR superfamily£©
LuUfdzH 4. antibody affinity maturation
*Z=:?4u 5. AP-1
,aQ{ 6. single chain variable fragment£¨ScFv£©
v6_fF5N/ 7. NK cell receptor
_^"0"<, 8. Zinkernagel-Doherty phenomenon
9 54O=9PQ 9. Ig fold
Dwp-*QK^G 10. CD40/CD40L
xHY#" ¶þ. ÎÊ´ðÌ⣨ÿÌâ12·Ö£¬¹²36·Ö£©
&^!vi2$5} 1. ÊÔÊöÐØÏÙ΢»·¾³¶ÔÐØÏÙϸ°ûµÄÑ¡Ôñ×÷Óü°ÆäÓëTϸ°û¹¦ÄÜÐÔÑÇȺÐγɵĹØÏµ¡£
982n G-" 2. ÊÔÊöÌåÒºÃâÒßÓ¦´ðµÄ¹æÂÉ£¬»ØÒä·´Ó¦ºÍ¿¹ÌåÀà±ðת»»µÄ»úÖÆÊÇʲô£¿
@u}1 S1 3. ÊԴӽṹºÍ¹¦ÄܵȽǶȣ¬²ûÊö°×ϸ°û·Ö»¯¿¹Ô£¨CD£©¡¢Õ³¸½·Ö×Ó£¨integrin£©ºÍÃâÒßÇòµ°°×³¬¼Ò×壨IgSF£©ÈýÀà·Ö×ÓµÄÏ໥¹ØÏµ¡£Ä¿Ç°ÔÚÕâÒ»ÁìÓòÖÐÖ÷ÒªÑо¿ÈȵãÊÇʲô£¿
1'>wrGr Èý. ÎÊ´ðÌ⣨24·Ö£¬µÚ1ÌâΪÃâÒßѧרҵ¿¼ÉúÊÔÌ⣬µÚ2ÌâΪѪҺ²¡Ñ§¿Æ¿¼ÉúÊÔÌ⣬µÚ3ÌâΪÏû»¯ÄÚ¿Æ¿¼ÉúÊÔÌ⣬ֻÔÊÐí´ð±¾×¨ÒµÊÔÌ⣩
mU3 @|a/@0 1. ÊԱȽÏTCRºÍBCR½á¹¹¼°Æäʶ±ð¿¹Ô¡¢ÁܰÍϸ°û»î»¯ÐźŵķÖ×Ó»úÀí¡££¨ÃâÒßѧרҵ£©¡£
1'
{A,! 2. ÊÔÊö°×Ѫ²¡ÃâÒßѧ·ÖÐÍÀíÂۺͷ½·¨µÄÑо¿½øÕ¹¡££¨ÑªÒº²¡Ñ§×¨Òµ£©¡£
F7~T=X)1 3. ÊÔÊöÖ×ÁöÒßÃçµÄÑо¿½øÕ¹¡££¨Ïû»¯ÄÚ¿Æ×¨Òµ£©¡£
r.T!R6v} Ò»¾Å¾Å°ËÄ격ʿÑо¿ÉúÈëѧ¿¼ÊÔÊÔÌâ
l;C00ZBOc £¨ÃâÒßѧרҵºÍרҵ»ù´¡£©
.Q^8_'ZG Ò».Ãû´Ê½âÊÍ£¨Ã¿Ìâ3·Ö£¬¹²45·Ö£©
K_X10/#b& 1.Co-stimulators (or co-stimulating molecules)
5D#Mhgun 2.NK-kB
`swf~ 3.Immunoglobulin superfamily
Y={_o!9 4.antigen-presenting cell (APC)
z|:3,$~sN 5.death domain
R!8 qkG 6.CCR and CXCR
~Kr_[X:d5 7.Lectin (or mitogen)
x&SG gl 8.Clusters of differentiation, CD)
`X06JTqf: 9.B7 family
lSu\VCG 10.Cytotoxic T lymphocyte, CTL)
L\u6EMyV 11.IL-15 and IL-15 receptor (IL-15R)
l6wN&JHTh 12.MHC restriction
Tz
Jp3 13.Affinity-chromatography
cy6lsJ"? 14.Cyctosprin A, CsA
G2A^+R0\ 15.Antibody-dependent cell-mediated cytotoxicity, ADCC)
B?cn5 ¶þ.ÎÊ´ðÌ⣨ÿÌâ10·Ö£¬¹²30·Ö£©
2!u4nxZ. 1.ºÎΪTh1ºÍ Th2ÑÇȺ£¿ÈçºÎ¼ì²â£¿ÔÚÁÙ´²ÉÏÓкÎÒâÒ壿
M+akD 2.ÊÔÊöÃâÒßÇòµ°°×£¨Ig£©µÄ½á¹¹Ó빦ÄܵĹØÏµ¡£
nF8|*}w 3.ÊԱȽÏTϸ°ûÊÜÌ壨TCR/CD3£©ÓëBϸ°ûÊÜÌ壨BCR£©µÄ×é³É¡¢½á¹¹¼°Æäʶ±ð ¿¹ÔµÄÌØµã¡£
?%RN? O( Èý.Ñ¡ÔñÎÊ´ðÌ⣨¸÷רҵ¿¼ÉúÖ»´ðÒ»µÀ±¾×¨ÒµÊÔÌ⣬25·Ö£©
tS2Orzc>, ÃâÒßѧרҵ£º
EO<{Bj=2 1.ÊÔÊöB7/CD28, CTLA-4£¬CD40/CD40L£¬LFA-1/ICAM-1£¬CD2/LFA-3µÄ½á¹¹¡¢·Ö²¼ÒÔ¼°Ï໥×÷Óúó½éµ¼µÄÖ÷ÒªÉúÎïѧ¹¦ÄÜ¡£
-f+U:/'.>v Ïû»¯ÄÚ¿Æ£º
eB$S d 2.Ö×Áö¿¹Ô·ÖΪÄļ¸Àࣿ»úÌ忹Ö×ÁöÃâÒßÖ÷ÒªÓÐÄÄЩÒòËØ£¨»úÖÆ£©£¿¼òÊöÌá¸ß¿¹Ö×ÁöÃâÒßÑо¿µÄÂԲߡ£
_.ny<r:g ѪҺ²¡Ñ§×¨Òµ£º
X~`<ik{q 3.ºÎΪ°×Ѫ²¡µÄÃâÒßѧ·ÖÐÍ£¿ºÎÎªÒÆÖ²ÎËÞÖ÷·´Ó¦£*****VHR£©£¿GVHR·¢ÉúµÄÖ÷ÒªÔÒò£¨Ìõ¼þ£©ÊÇʲô£¿
<d$L}uQwg Ò»¾Å¾ÅÄê¾Å²©Ê¿ÉúÈëѧ¿¼ÊÔÊÔÌâ
zO)>(E? (רҵ»ù´¡: ÃâÒßѧ)
sC/5N Ò».Ãû´Ê½âÊÍ(ÿÌâ5·Ö,¹²45·Ö)
5L'b
F2SI 1. ADCC(antibody dependent cell-mediated cytotoxicity)
Guc~]
B 2. »·æß¾úËØ(cyclosporin)
C1/<t)^ 3. KIR(killer cell inhibitory receptor)
&s +DK` 4. HLDA(human leucocyte differentiation antigen)
DQ<{FN 5. Interleukin 18(IL-18)
`qNhB\ 6. ÕûºÏËØ(integrin)
kiW|h)w_,v 7. Fas/FasL
(Hr_gkGtM 8. FcR(ÃâÒßÇòµ°°×Fc¶ÎÊÜÌå)
Z#+{ksU 9. ϸ°û¼äÕ³¸½·Ö×Ó(ICAM)
xHA6 10. Th1/Th2
+}XFkH
~ 11. »ùÒòÒßÃç(DNAÒßÃç)
vS! TnmF 12. chemokines and chemokine receptor
jLANv{" 13. ÃâÒßÄÍÊÜ
A,tmy',d" 14. ¹²´Ì¼¤·Ö×Ó
r[>=iim 15. ËÀÍö½á¹¹Óò(death domain)
ZB+N[VJs) ¶þ.ÎÊ´ðÌâ(µÚ1¡¢2Ìâ¸÷18·Ö,µÚ3Ìâ19·Ö)
[h
LSK-K 9 1. ÊԱȽÏɱÉËÐÔTϸ°û(CTL)Óë×ÔȻɱÉËϸ°û(NK)ÔÚɱÉ˰Ðϸ°û¹ý³ÌÖÐ,ʶ±ðϸ°û¶¾¼°½éµ¼ÃâÒß¹¦ÄÜÓкβ»Í¬?
-QUr|:SK: 2. 70Äê´úÒÔÀ´,ÓйØIgºÍÌåÒºÃâÒßÑо¿´æÔÚÒÔϼ¸ÏîÖØ´ó·¢ÏÖºÍÍ»ÆÆ¶ø»ñµÃҽѧºÍÉúÎïѧŵ±´¶û½±,Çë·Ö±ð²ûÊöËüÃǵÄÀíÂÛÒâÒå¼°ÔÚҽѧʵ¼ùÖеÄÓ¦Óá£
_T
B,2 R £¨1£©1972Ä꣺θµ°°×øºÍľ¹Ïµ°°×øˮ½âIg£¬»ñµÃFab¡¢Fc¡¢F£¨ab¡¯£©2µÈƬ¶Î
` )9nBZ £¨2£©1977Ä꣺·ÅÉäÃâÒß·¨
;1S~'B&1Q £¨3£©1984Ä꣺ÁܰÍϸ°ûÔÓ½»ÁöºÍµ¥¿Ë¡¿¹Ìå
#HMJBQ4v# £¨4£©1987Äê: Ig»ùÒòµÄ½á¹¹
%gF; A* 3. ½üÄêÀ´ÔÚÖ×ÁöÃâÒßÑо¿ÁìÓòÖÐÓÐÄÄÐ©ÖØÒª½øÕ¹?ÊÔÊöµ±Ç°Ìá¸ß»úÌ忹Ö×ÁöÃâÒßµÄÖ÷Òª²ßÂÔ¡£
*5SOXrvhu6 Ò»¾Å¾Å¾ÅÄ격ʿÉúÈëѧ¿¼ÊÔÊÔÌâ(ÃâÒßѧרҵ)
^-s'Ad3 ÎÊ´ðÌâ(ÿÌâ25·Ö)
8Z=d+}Gg< 1. ÊԱȽÏTϸ°ûÊÜÌ壨TCR£©¡¢Bϸ°ûÊÜÌ壨BCR£©ºÍNKϸ°ûÊÜÌ壨NKCR£©µÄ×é³É£¬Ê¶±ðÅäÌåÒÔ¼°ÐźÅתµ¼µÄÒìͬµã¡£
~1x,m.f8 2. ÒÔÐØÏÙÒÀÀµ¿¹Ô´Ì¼¤»úÌå²úÉú¿¹ÌåµÄÃâÒßÓ¦´ðΪÀý£¬Tϸ°ûºÍBϸ°ûÊÇÈçºÎÏ໥×÷Óã¿ÓÐÄÄЩճ¸½·Ö×Ӻ͹²´Ì¼¤·Ö×Ó²ÎÓëT¡¢Bϸ°ûµÄÏ໥×÷Óã¿
[D]9M"L,vQ 3. Éö×ÛºÏÕ÷³öѪÈÈ(HFRS)²¡¶¾µÄ½á¹¹»ùÒòÒѾ¸ãÇå³þ,ΪÁË֤ʵHFRS²¡¶¾¸ÐȾ»úÌå(ÒÔBalb/CСÊóΪÀý)¿É²úÉúHFRS²¡¶¾ºËÒ¿ǵ°°×(NP)ÌØÒìÐÔCTL,²¢ÔÚÃâÒß·À»¤ÖÐÆðÖØÒª×÷ÓÃ,ÇëÓ¦ÓÃÃâÒßѧÀíÂۺͷ½·¨,Éè¼ÆÒ»ÏµÍ³ÊµÑé,¼ÓÒÔ֤ʵ¡£
9?VyF'r= 4. Àý¾Ù¶þ¸ö½üÄêÀ´Ï¸°ûºÍ·Ö×ÓÃâÒßѧÑо¿ÖгöÏÖµÄеÄÈȵã,Çë·Ö±ðÆÀÊöÆäÑо¿ÒâÒå¡¢·¢Õ¹Ç÷ÊÆÒÔ¼°Ó¦ÓÃǰ¾°¡£